US3691016A
(en)
|
1970-04-17 |
1972-09-12 |
Monsanto Co |
Process for the preparation of insoluble enzymes
|
CA1023287A
(en)
|
1972-12-08 |
1977-12-27 |
Boehringer Mannheim G.M.B.H. |
Process for the preparation of carrier-bound proteins
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
US4195128A
(en)
|
1976-05-03 |
1980-03-25 |
Bayer Aktiengesellschaft |
Polymeric carrier bound ligands
|
US4330440A
(en)
|
1977-02-08 |
1982-05-18 |
Development Finance Corporation Of New Zealand |
Activated matrix and method of activation
|
CA1093991A
(en)
|
1977-02-17 |
1981-01-20 |
Hideo Hirohara |
Enzyme immobilization with pullulan gel
|
US4229537A
(en)
|
1978-02-09 |
1980-10-21 |
New York University |
Preparation of trichloro-s-triazine activated supports for coupling ligands
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
US5374548A
(en)
|
1986-05-02 |
1994-12-20 |
Genentech, Inc. |
Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
MX9203291A
(es)
|
1985-06-26 |
1992-08-01 |
Liposome Co Inc |
Metodo para acoplamiento de liposomas.
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
IL89220A
(en)
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
ES2195036T3
(es)
|
1995-12-22 |
2003-12-01 |
Bristol Myers Squibb Co |
Conectores de hidrazona ramificados.
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
EP2266607A3
(en)
|
1999-10-01 |
2011-04-20 |
Immunogen, Inc. |
Immunoconjugates for treating cancer
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
IT1320715B1
(it)
|
2000-10-19 |
2003-12-10 |
Cselt Centro Studi Lab Telecom |
Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
WO2003011161A1
(en)
|
2001-08-03 |
2003-02-13 |
Tyco Healthcare Group Lp |
Tissue marking apparatus and method
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
AU2003275126A1
(en)
|
2002-09-20 |
2004-04-08 |
Wyeth Holdings Corporation |
Hemiasterlin derivatives for treating resistant tumors
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
JP2006507322A
(ja)
|
2002-11-14 |
2006-03-02 |
シンタルガ・ビーブイ |
多重自己脱離放出スペーサーとして構築されたプロドラッグ
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
PT1651162E
(pt)
|
2003-05-20 |
2016-02-22 |
Immunogen Inc |
Agentes citotóxicos melhorados compreendendo novos maitansinóides
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
DK1725249T3
(en)
|
2003-11-06 |
2014-03-17 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugating to ligands.
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
WO2005112919A2
(en)
|
2004-05-19 |
2005-12-01 |
Medarex, Inc. |
Self-immolative linkers and drug conjugates
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
US8158590B2
(en)
|
2005-08-05 |
2012-04-17 |
Syntarga B.V. |
Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
|
AU2006299429B2
(en)
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
EP1994000B1
(en)
|
2006-02-02 |
2017-08-23 |
Syntarga B.V. |
Water-soluble cc-1065 analogs and their conjugates
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP2173739B1
(en)
|
2007-08-01 |
2013-07-31 |
Syntarga B.V. |
Substituted cc-1065 analogs and their conjugates
|
EA026990B1
(ru)
|
2007-11-07 |
2017-06-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающиеся с человеческой клеткой dec-205
|
US8540998B2
(en)
|
2007-12-24 |
2013-09-24 |
Oxford Biotherapeutics Ltd. |
Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents
|
HUE035798T2
(en)
|
2008-11-03 |
2018-05-28 |
Syntarga Bv |
CC-1065 analogues and conjugates
|
GB201220010D0
(en)
*
|
2012-11-07 |
2012-12-19 |
Oxford Biotherapeutics Ltd |
Therapeutic amd diagnostic target
|
EP3055331B1
(en)
*
|
2013-10-11 |
2021-02-17 |
Oxford Bio Therapeutics Limited |
Conjugated antibodies against ly75 for the treatment of cancer
|
CN106146508A
(zh)
*
|
2015-03-19 |
2016-11-23 |
浙江导明医药科技有限公司 |
优化的联合用药及其治疗癌症和自身免疫疾病的用途
|
KR20180061226A
(ko)
*
|
2015-09-11 |
2018-06-07 |
와이즈에이씨가부시키가이샤 |
항cd26 항체와 다른 항암제를 조합한 암 치료용 조성물
|
KR102124715B1
(ko)
*
|
2015-11-03 |
2020-06-18 |
제넨테크, 인크. |
암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물
|
EP3442584B1
(en)
*
|
2016-03-15 |
2021-07-28 |
Seagen Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
CA3030837A1
(en)
*
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
KR102500868B1
(ko)
*
|
2016-10-28 |
2023-02-16 |
모르포시스 아게 |
항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
|
GB201703876D0
(en)
*
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
GB201711785D0
(en)
*
|
2017-07-21 |
2017-09-06 |
Berlin-Chemie Ag |
Antibodies
|
US11524078B2
(en)
*
|
2020-05-14 |
2022-12-13 |
Delta-Fly Pharma, Inc. |
Water-soluble macromolecular derivative of Venetoclax
|